Drag a card by its title · ⚙ to size, swap or remove

The company

Cingulate Inc.

CING · Nasdaq

Health CareBiotechnologyNot moving yet

CING stood above a rising 150-day average in 19 of the last 52 weekly readings, and has been out of that trend for the last 23 weeks. It is 16.4% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 23
Industry in uptrend: 15% -17 in 4 wk
Insider buys, 12 months: $1.3M
Insider sales, 12 months: $0
Officials’ trades on record: 0
Institutions holding: 31 (+6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 19 of 52 weeks.

17 Apr – 16 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months5

Sale orders, 12 months0

Buyers · sellers5 · 0

Who	Did	Shares	Traded
Thomas Jeffrey HargrovesDirector	bought	97,276at $5.04	13 Feb 2026filed 8 Jun 2026
Thomas Jeffrey HargrovesDirector	bought	77,821at $0.10	13 Feb 2026filed 8 Jun 2026
Matthew BramsEVP and Chief Medical Officer	bought	1,946at $5.04	6 Feb 2026filed 10 Feb 2026
Matthew BramsEVP and Chief Medical Officer	bought	1,556at $0.10	6 Feb 2026filed 10 Feb 2026
Shane J. SchafferChief Executive Officer	bought	6,809at $5.04	6 Feb 2026filed 10 Feb 2026
Shane J. SchafferChief Executive Officer	bought	5,447at $0.10	6 Feb 2026filed 10 Feb 2026
Jennifer L. CallahanSVP and CFO	bought	4,864at $5.04	6 Feb 2026filed 10 Feb 2026
Jennifer L. CallahanSVP and CFO	bought	3,891at $0.10	6 Feb 2026filed 10 Feb 2026
Peter J. WerthDirector	bought	19,455at $5.04	6 Feb 2026filed 10 Feb 2026
Peter J. WerthDirector	bought	15,564at $0.10	6 Feb 2026filed 10 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders31+6 on the quarter

New · exited9 · 3

Reported value$9.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	570,873$3.1M	+261,906+84.8%
Chicago Partners Investment Group LLCadded · filed 30 Jul 2026	188,429$912K	+169,679+905.0%
RAYMOND JAMES FINANCIAL INCnew · filed 14 Aug 2026	166,898$913K	+166,898
Kestra Advisory Services, LLCadded · filed 28 Jul 2026	151,500$829K	+11,500+8.2%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026	144,636$791K	+43,263+42.7%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026	127,500$697K	+95,612+299.8%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026	79,160$433K	+29,086+58.1%
BlackRock, Inc.added · filed 7 Aug 2026	53,130$291K	+29,861+128.3%
BCV Asset Management Inc.unchanged · filed 10 Aug 2026	51,200$273K	00.0%
STATE STREET CORPadded · filed 7 Aug 2026	47,888$262K	+20,300+73.6%